1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo ...
1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events ...
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more ...
1. Baseline mGPS measures reliably predict the prognostic outcome of treatment in patients with metastatic renal cell carcinoma (mRCC) 2. ...
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
1. Reduced median overall survival associated with annual rate of change in circulating tumour cell (CTC) abundance >0.12 CTCs/mL 2. ...
